AFT Pharmaceuticals Releases Financial Results

AFT Pharmaceuticals (ASX:AFP) has released its financial results for the first half of 2025. The company reported a revenue increase of 4% to NZ$86.7 million, driven by growth in its Australasian operations. However, it faced an operating loss of NZ$1.8 million due to international challenges.

AFT Pharmaceuticals Outlook and Strategy

AFT Pharmaceuticals has outlined a strategic plan for growth despite challenges in international markets. The company achieved strong revenue growth in Australia and New Zealand but faced setbacks in Asia due to a doctors' strike and customer destocking. AFT is focusing on expanding its product portfolio and entering new markets, with targets of reaching NZ$300 million in annual revenue by FY2027. The company is optimistic about a recovery in profitability in the second half of the fiscal year, with a projected operating profit between NZ$15 million to NZ$20 million by March 2025. Strategic partnerships, R&D investment, and financial health remain key priorities for AFT's future growth.

Executive Commentary on Financial Results

While we are pleased with the growth in our Australasian operations, the challenges faced internationally have impacted our overall performance. We are optimistic about the second half of the year, with new product launches and the return to normal trading conditions.